JCM
AKBA icon

JS Capital Management’s Akebia Therapeutics AKBA Stock Holding History

JS Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-14,600
Closed -$37K – 139
2020
Q3 		$37K Buy
+14,600
New +$128K ﹤0.01% 137

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

JS Capital Management's AKBA Position: Q4 2020 in Review

JS Capital Management sold out of Akebia Therapeutics (AKBA) in Q4 2020, closing a stake of 14,600 shares — an estimated $37K sold.

JS Capital Management first reported a position in AKBA in Q3 2020 and held it in 1 quarter. The position peaked at $37K in Q3 2020. 143 funds tracked by Wall St. Rank hold AKBA as of Q4 2020.

  • JS Capital Management reported no remaining Akebia Therapeutics position as of Q4 2020 after selling out during the quarter.
  • JS Capital Management sold 14,600 Akebia Therapeutics shares in Q4 2020, an estimated $37K.
  • JS Capital Management first reported a position in Akebia Therapeutics in Q3 2020 and held it in 1 quarter.
  • JS Capital Management's Akebia Therapeutics position peaked at $37K in Q3 2020.
  • 143 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2020.

Based on JS Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.